+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Phenylketonuria Treatment Market (2021-2026) by Type, Route, End-user, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis

  • PDF Icon


  • 185 Pages
  • April 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5317157
UP TO OFF until Sep 30th 2022
The Global Phenylketonuria Treatment Market is estimated to be USD 540.6 Mn in 2021 and is expected to reach USD 723.4 Mn by 2026, growing at a CAGR of 6%.

Key factors like the development of pipeline drugs against PKU along with market collaborations amongst the players have supported the growth of this market. Growing incidences of PKU patients worldwide is a major factor driving the growth of the global market. Several other factors, such as increasing investments in intensive research in the genomics field and increasing awareness regarding the timely treatment of PKU are responsible for spurring the growth of the phenylketonuria treatment market.

However, a high cost associated with the treatment of PKU, along with low awareness amongst the patients about the disease, has impeded the market growth.

Market Dynamics

  • Increasing Prevalence of Phenylketonuria
  • Presence of Pipeline Drugs
  • Rising Collaborations among Key Market Players

  • High Cost of Treatment
  • Stringent Government Regulations

  • Increasing Development and Commercialization of New Drugs
  • Advancements in the Health Care Industry

  • Lack of Awareness among the Patients and Physicians

  • Growing research in the field of genomics and bioinformatics

Segments Covered

By Type, the Drugs segment is anticipated to grow at a faster pace in the forecasted period. It is because phenylketonuria is a rare genetic disorder with very few available treatment options so far. Healthcare professionals have widely promoted prescription drugs along with some dietary modifications. Out of which, Kuvan, a medical drug approved by the US FDA has been used for the treatment in tablet and powder form. Similarly, Biopten, manufactured by Daiichi Sankyo Co. Limited, has been approved by Japan, indicating the demand for this segment.

By Route Analysis, the Oral Route is anticipated to grow at a faster pace during the forecasted period. It is mainly due to the patients’ convenience for consumption and is also considered as an easy way of administration over intravenous injections/ infusions.

By End User, the Hospital Pharmacies segment holds a major share of the market as they ensure the safe and effective use of medicines by carrying out medication reconciliation on admissions and changes in care level.

By Geography, North America is expected to lead the market. The factors attributing to the growth of this market are the favorable regulations and the Government initiatives towards the treatment of PKU, a rise in the number of new-born cases suffering from phenylketonuria, and a strong healthcare infrastructure system in the region. Additionally, there have been continuous R&D activities for the development and commercialization of new drugs for PKU, which has further promoted the growth of this market.

The Global Phenylketonuria Treatment Market is further segmented on the basis of Type, Route, End-User, and Geography.

Global Phenylketonuria Treatment Market, By Type
  • Introduction
  • Drugs
  • Kuvan
  • Bipten
  • Dietary Supplements

Global Phenylketonuria Treatment Market, By Route
  • Introduction
  • Oral
  • Tablets and Capsules
  • Syrups
  • Powder
  • Parenteral
  • Intravenous
  • Subcutaneous

Global Phenylketonuria Treatment Market, By End User
  • Introduction
  • Hospitals
  • Drug Store
  • Online Pharmacies
  • Paediatric Clinics
  • Others

Global Phenylketonuria Market, By Geography
  • Introduction
  • North America
  • South America
  • Europe
  • Asia Pacific
  • The Middle East and Africa

Company Profiles

Some of the companies covered in this report are BioMarin Pharmaceuticals, Inc., Censa Pharmaceutical, Inc., Retrophin, Inc., Synlogic, Inc., Rubius Therapeutics, Inc., and Homology Medicines, Inc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance Score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.
Bulls: Companies that are medium in size competing with their USPs, growing companies with proven market share.
Rabbits: Small companies but growing rapidly, constantly improving their offerings in the market.
Tortoise: Companies which are slow in growth, having a long legacy, and stable or negative in performance.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Phenylketonuria Treatment Market.
  • The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
  • The report also contains the competitive analysis using Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Report Highlights:
  • A complete analysis of the market including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Phenylketonuria Treatment Market

What is the estimated value of the Global Phenylketonuria Treatment Market?

The Global Phenylketonuria Treatment Market was estimated to be valued at $540.6 Million in 2021.

What is the growth rate of the Global Phenylketonuria Treatment Market?

The growth rate of the Global Phenylketonuria Treatment Market is 6.0%, with an estimated value of $723.4 Million by 2026.

What is the forecasted size of the Global Phenylketonuria Treatment Market?

The Global Phenylketonuria Treatment Market is estimated to be worth $723.4 Million by 2026.

Who are the key companies in the Global Phenylketonuria Treatment Market?

Key companies in the Global Phenylketonuria Treatment Market include Homulogy Medicines, Inc., Rubius Therapeutics. Inc., Retrophin, Inc., Synlogic, Inc., BioMarin Pharmaceutical Inc., Daiichi Sankyo Company, Limited, Codexis, Inc., SOM Innovation Biotech SL and Erytech Pharma SA.

Table of Contents

1. Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2. Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.3 Trends
5. Market Analysis
5.1 Porter’s Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6. Global Phenylketonuria Treatment Market, By Type
6.1 Introduction
6.2 Drugs
6.2.1 Kuvan
6.2.2 Bipten
6.3 Dietary Supplements
7. Global Phenylketonuria Treatment Market, By Route
7.1 Introduction
7.2 Oral
7.2.1 Tablets and Capsules
7.2.2 Syrups
7.2.3 Powder
7.3 Parenteral
7.3.1 Intravenous
7.3.2 Subcutaneous
8. Global Phenylketonuria Treatment Market, By Route
8.1 Introduction
8.2 Hospital Pharmacies
8.3 Drug Stores
8.4 Online Pharmacies
8.5 Pediatric Clinics
8.6 Others
9. Global Phenylketonuria Treatment Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 South America
9.3.1 Brazil
9.3.2 Argentina
9.4 Europe
9.4.1 UK
9.4.2 France
9.4.3 Germany
9.4.4 Italy
9.4.5 Rest of Europe
9.5 Asia-Pacific
9.5.1 China
9.5.2 Japan
9.5.3 India
9.5.4 Australia
9.5.5 Rest of APAC
9.6 Middle East and Africa
10. Competitive Landscape
10.1 Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreements, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Fundings
11. Company Profiles
11.1 Homulogy Medicines, Inc.
11.2 Rubius Therapeutics. Inc.
11.3 Retrophin, Inc.
11.4 Synlogic, Inc.
11.5 BioMarin Pharmaceutical Inc.
11.6 Daiichi Sankyo Company, Limited
11.7 Codexis, Inc.
11.8 SOM Innovation Biotech SL
11.9 American Gene Technologies International Inc.,
11.10 Erytech Pharma SA
11.11 Dimension Therapeutics, Inc.
11.12 Synthetic Biologics, Inc.
12. Appendix
12.1 Questionnaire

Companies Mentioned

  • Homulogy Medicines, Inc.
  • Rubius Therapeutics. Inc.
  • Retrophin, Inc.
  • Synlogic, Inc.
  • BioMarin Pharmaceutical Inc.
  • Daiichi Sankyo Company, Limited
  • Codexis, Inc.
  • SOM Innovation Biotech SL
  • American Gene Technologies International Inc.,
  • Erytech Pharma SA
  • Dimension Therapeutics, Inc.
  • Synthetic Biologics, Inc.